HeartSciences (HSCSW) EBIT (2021 - 2026)

HeartSciences has reported EBIT for 6 years, with the latest figure at -$1.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 18.66% year-over-year to -$1.9 million; the trailing twelve-month figure through Jan 2026 stood at -$7.8 million (up 6.2% YoY), and the FY2025 full-year result was -$8.4 million, down 32.46% from the prior year.
• EBIT for Q1 2026 stood at -$1.9 million, up from -$2.1 million in the prior quarter.
• The five-year high for EBIT was -$1.1 million in Q1 2022, with the low at -$2.4 million in Q1 2025.
• Historically, EBIT has averaged -$1.7 million across 5 years, with a median of -$1.9 million in 2025.
• Annual changes were most pronounced in 2022 — EBIT sank 112.04% — and 2023, when it climbed 19.17%.
• HeartSciences' EBIT stood at -$1.8 million in 2022, then advanced by 11.55% to -$1.6 million in 2023, then decreased by 26.44% to -$2.0 million in 2024, then declined by 4.45% to -$2.1 million in 2025, then increased by 6.97% to -$1.9 million in 2026.
• The last three EBIT figures came in at -$1.9 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.